Home  /  Resource Library  /  Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study

Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study

Results of a phase II trial investigating the combination of ibrutinib, rituximab and lenalidomide for first line treatment of follicular or marginal zone lymphomas.